Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA has announced promising interim results from its Phase 2 NeoCOAST-2 study, showcasing the potential of monalizumab in combination with durvalumab and chemotherapy to improve outcomes in early-stage non-small cell lung cancer (NSCLC). The data, presented at the World Conference on Lung Cancer, indicated a higher pathological complete response rate than the current approved regimen, with a manageable safety profile. These findings support the continued investigation of monalizumab as a means to enhance the clinical benefit of existing NSCLC treatments.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
